Canadian Universities Spearheading Advances in DNA Repair and Pancreatic Cancer Immunotherapy

Pancreatic cancer remains one of the most formidable challenges in oncology, with a five-year survival rate hovering around 12 percent in Canada. However, researchers at leading Canadian universities are uncovering how defects in DNA repair genes—known as DNA damage repair or DDR pathways—can transform this deadly disease into a target for immunotherapy. These genetic vulnerabilities create opportunities for immune checkpoint inhibitors to unleash the body's defenses against tumors that were previously resistant to treatment. Institutions like the University of British Columbia, University of Toronto, McGill University, and Queen's University are at the forefront, driving clinical trials and genomic studies that promise personalized therapies tailored to individual patients' genetic profiles.

The focus on DDR genes such as BRCA1, BRCA2, ATM, POLE, and FANCA has gained momentum because these mutations impair a cancer cell's ability to fix DNA damage. This leads to genomic instability, higher mutation loads, and the production of neoantigens—abnormal proteins that the immune system can recognize. Canadian higher education institutions are not only advancing the science but also training the next generation of oncologists and geneticists through specialized PhD programs in interdisciplinary oncology.

Understanding DNA Repair Defects in Pancreatic Cancer

DNA repair genes play a crucial role in maintaining genomic integrity by fixing breaks, mismatches, and other damage that occur during cell division. In pancreatic ductal adenocarcinoma—the most common form—these pathways are frequently mutated, leading to synthetic lethality when targeted with drugs like PARP inhibitors (poly ADP-ribose polymerase inhibitors). Olaparib, a PARP inhibitor, is already approved in Canada for maintenance therapy in BRCA-mutated metastatic pancreatic cancer following platinum-based chemotherapy.

Step-by-step, here's how DDR defects intersect with immunotherapy: First, mutations cause replication stress and double-strand breaks. Second, unrepaired damage accumulates mutations, increasing tumor mutational burden (TMB). Third, this generates neoantigens, making tumors visible to T cells. Immune checkpoint inhibitors like durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) then block inhibitory signals, allowing T cells to attack. Canadian researchers have shown that patients with multiple DDR hits respond dramatically better, extending survival from months to years.

This synergy is particularly relevant in Canada, where pancreatic cancer incidence is rising due to aging populations and diabetes prevalence, affecting over 3,500 new cases annually. University labs are dissecting these mechanisms using CRISPR screens and whole-genome sequencing, providing actionable insights for clinical practice.

The Groundbreaking CCTG PA.7 Trial Led by Canadian Institutions

The Canadian Cancer Trials Group (CCTG), based at Queen's University, spearheaded the PA.7 phase II trial—a multicenter effort involving 28 sites across Canada. Published in early 2026, the study compared standard gemcitabine plus nab-paclitaxel chemotherapy with the addition of dual immunotherapy (durvalumab and tremelimumab) in 180 patients with metastatic pancreatic ductal adenocarcinoma.

Overall, immunotherapy did not improve median overall survival (9.84 vs. 8.76 months). However, plasma sequencing revealed that 10.4 percent of patients had concurrent mutations in BRCA1, POLE, ATM, and FANCA. Those with two or more DDR mutations (11 patients in immunotherapy arm) saw median survival jump to 26.2 months versus 9.7 months on chemo alone—a hazard ratio of 0.34. Progression-free survival was 14.6 vs. 5.3 months.This landmark finding positions DDR profiling as a biomarker for immunotherapy selection.

Key contributors included Dr. Daniel J. Renouf from BC Cancer and UBC, Dr. Jennifer Knox from Princess Margaret Cancer Centre and U Toronto, and teams from McGill's Segal Cancer Centre. Queen's CCTG coordinated the trial, highlighting collaborative higher education networks.

University of Toronto's Pioneering Labs and Discoveries

At U Toronto, the Donnelly Centre for Cellular and Biomolecular Research has identified APOBEC3C and APOBEC3D as culprits in gemcitabine resistance. These enzymes activate during chemotherapy-induced DNA replication stress, aiding repair and cell survival. Knocking them out via CRISPR destabilizes the genome, killing pancreatic cells—a potential combo with immunotherapy. Professor Grant Brown notes, “We discovered a more direct role for the enzymes, where they actually protect pancreatic cancer cells from gemcitabine therapy.” Full details here.

Nearby, Sinai Health's Lunenfeld-Tanenbaum Research Institute, affiliated with U Toronto, pinpointed USP15 and SCAF1 as tumor suppressors. Mutations in these genes, affecting up to 30 percent of cases, drive aggressive growth but sensitize tumors to chemotherapy. Dr. Daniel Schramek's team used in vivo CRISPR screens: “While mutations make tumours more aggressive, they also sensitize tumours towards standard chemotherapy.” Explore the study.

Princess Margaret Cancer Centre contributes through PanCuRx (OICR), sequencing tumors for DDR signatures to guide PARP inhibitors and immunotherapy.

McGill University and RI-MUHC: Overcoming Immunotherapy Resistance

McGill's Research Institute of the McGill University Health Centre (RI-MUHC) is targeting pancreatic cancer's "Achilles heel"—a vulnerability enabling combination therapies. Recent 2026 work from the Lebrun lab uses CRISPR to identify drivers, paving ways for immunotherapy sensitization. Segal Cancer Centre participated in PA.7, validating DDR biomarkers.

McGill's Interdisciplinary Cancer Sciences PhD trains students in these areas, fostering expertise in genomic immunotherapy.

Photo by National Cancer Institute on Unsplash

UBC and BC Cancer: Precision Medicine at the Pancreas Centre

UBC's BC Cancer Pancreas Centre BC, led by Dr. Renouf, drives PA.7 and HRD research. Studies show homologous recombination deficiency (HRD) predicts PARP response, linking to immunotherapy via neoantigen load. UBC's Interdisciplinary Oncology PhD program recruits for such labs.

National Profiling Initiatives: EPPIC and PanCuRx

The Terry Fox Research Institute's EPPIC profiles 400 metastatic cases across UBC, U Calgary, U Alberta, Queen's, and McGill, identifying BRCA/DDR for platinums and PARP-i. "Precision medicine may hold the key," says TFRI. Learn more. OICR's PanCuRx complements with subtypes for immunotherapy.

Training Future Experts: PhD and MSc Programs in Canada

Canadian universities offer robust graduate training. UBC's PhD in Interdisciplinary Oncology emphasizes cancer genomics. McGill's ICSP PhD integrates immunology. Queen's Cancer Research Collaboration PhD leverages CCTG trials. UAlberta's Cancer Sciences PhD funds DDR projects. These programs provide hands-on lab experience, funding via CIHR/Terry Fox, preparing students for research careers.

Funding Fuels Collaborative Research

CIHR, Terry Fox New Frontiers ($4M EPPIC), Riddell Centre grants support immunotherapy trials. Multi-uni collaborations amplify impact, with PhD stipends enabling deep dives into DDR mechanisms.

Clinical Implications and Future Outlook

DDR testing via ctDNA is non-invasive, guiding first-line therapy. Trials like PA.7 suggest 10 percent of patients could double survival. Canadian unis lead global efforts, with AI/genomics accelerating discoveries.

Photo by Google DeepMind on Unsplash

Careers in Cutting-Edge Cancer Research

Opportunities abound: postdocs at BC Cancer, faculty at U Toronto PMCC. /higher-ed-jobs/research-jobs lists roles. Skills in CRISPR, sequencing, immunology are prized.